Genotyping Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Capillary Electrophoresis is the fastest growing sector, North America is the largest market

The Global Genotyping Assay Market is projected to experience robust growth, expanding from USD 17.89 Billion in 2025 to USD 41.64 Billion by 2031, representing a CAGR of 15.12%. Genotyping assays, which are analytical solutions used to ascertain an organism's specific genetic makeup by comparing DNA sequences to a reference standard, are seeing increased demand due to the broader application of pharmacogenomics and the rising global incidence of genetic diseases requiring targeted therapies. This transition toward precision healthcare is supported by recent industry data; according to the 'Personalized Medicine Coalition' in '2025', 18 new personalized medicines were approved in the preceding year, making up approximately 38 percent of all newly approved therapeutic molecular entities.

Conversely, market progress faces a significant obstacle in the form of an increasingly complex regulatory framework governing diagnostic testing. In particular, tighter oversight and evolving compliance mandates regarding Laboratory Developed Tests create substantial hurdles for clinical laboratories and manufacturers. These regulatory uncertainties impose operational burdens that can delay the launch of innovative assays and increase development costs, thereby effectively constraining the rapid global scalability of genotyping solutions.

Market Drivers

Technological breakthroughs in high-throughput sequencing and PCR are fundamentally transforming the genotyping landscape, enabling laboratories to process extensive genetic data libraries with unmatched speed and accuracy. Next-generation sequencing platforms now facilitate the simultaneous analysis of multiple genomic regions, reducing per-sample costs and improving scalability for large-scale population studies, a shift evidenced by the rapid adoption of advanced instrumentation. According to Illumina Inc., February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company reported shipping 352 NovaSeq X instruments during the prior fiscal year, highlighting the industrial move toward high-capacity genomic infrastructure that ensures services remain accessible for applications ranging from basic research to complex diagnostics.

Simultaneously, the escalating global prevalence of chronic diseases and genetic disorders is driving the integration of genotyping into routine clinical workflows and drug discovery pipelines. As the burden of pathologies like cancer grows, healthcare providers increasingly depend on genomic profiling for biomarker identification and early detection; according to the American Cancer Society, January 2024, in 'Cancer Facts & Figures 2024', 2,001,140 new cancer cases are projected in the United States in 2024, creating an urgent need for precise diagnostic tools. To handle the resulting computational demands, substantial investments are targeting biobanking and informatics, such as the Novo Nordisk Foundation's 2024 commitment of approximately DKK 600 million to establish a state-of-the-art AI supercomputer to accelerate life sciences research.

Market Challenges

The expansion of the Global Genotyping Assay Market is notably impeded by the intricate regulatory environment surrounding diagnostic testing, particularly regarding the stricter oversight of Laboratory Developed Tests (LDTs). The shift to classify these tests as medical devices marks the end of enforcement discretion, compelling clinical laboratories to navigate rigorous premarket reviews and adhere to quality system mandates. This transition creates immediate operational challenges, forcing laboratories to divert capital and technical expertise away from innovating new genotyping assays and toward ensuring administrative compliance for their current inventories.

The scale of these regulatory hurdles directly limits market scalability by creating bottlenecks in test availability and driving up development costs. The sheer volume of assays requiring retroactive approval places a massive strain on resources; for instance, according to the 'American Hospital Association' in '2024', one major health system reported managing at least 1,600 existing Laboratory Developed Tests that would necessitate individual regulatory submissions under the new rules. Faced with such extensive filing requirements, laboratories are expected to streamline their test menus and postpone the introduction of advanced genotyping solutions, effectively stalling market expansion.

Market Trends

The rise of liquid biopsy genotyping applications is reshaping the market by facilitating non-invasive, real-time disease monitoring that bypasses the limitations of traditional tissue sampling. This trend is especially significant in precision oncology, where liquid biopsies enable the longitudinal analysis of circulating tumor DNA to identify emerging resistance mutations and guide dynamic therapeutic adjustments, a capability supported by growing clinical validation. Demonstrating this utility, according to Guardant Health, Inc., June 2025, in the 'SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test' press release, using the company’s liquid biopsy assay to detect emerging ESR1 mutations and switch therapies reduced the risk of disease progression or death by 56 percent in advanced breast cancer patients.

Concurrently, the growing adoption of digital PCR for precision quantification is propelling market growth as laboratories seek absolute nucleic acid measurement capabilities that exceed the sensitivity of quantitative PCR. This technology is becoming indispensable for detecting rare targets, such as in viral load monitoring and cell and gene therapy quality control, without requiring reference standards. Manufacturers are expanding their portfolios to meet this demand; according to Bio-Rad Laboratories, Inc., July 2025, in the 'Bio-Rad Expands Droplet Digital PCR Offering' press release, the company now offers more than 400,000 assays, significantly widening access to high-precision digital PCR solutions for clinical diagnostics and life science research.

Key Market Players

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen NV
• Agilent Technologies Inc.
• Danaher Corporation
• Hoffmann-La Roche Ltd.
• GE HealthCare Technologies Inc.
• Standard BioTools Inc.
• Eurofins Scientific SE
• Bio-Rad Laboratories Inc.

Report Scope

In this report, the Global Genotyping Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Assay Market, by Product & Service:

• Reagents & Kits
• Genotyping Services
• Instruments
• Sequencers & Amplifiers
• Analyzers
• Bioinformatics
• Software
• Services

Genotyping Assay Market, by Technology:

• PCR (Real-time PCR Digital PCR)
• Microarrays
• Sequencing
• Capillary Electrophoresis
• MALDI-TOF
• Others

Genotyping Assay Market, by Application:

• Pharmacogenomics
• Diagnostic & Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Other Applications

Genotyping Assay Market, by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostic and Research Laboratories
• Academic Institutes
• Others

Genotyping Assay Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Assay Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.